

Tiziana Latronico

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/943506/publications.pdf>

Version: 2024-02-01

32
papers

764
citations

489802

18
h-index

591227

27
g-index

32
all docs

32
docs citations

32
times ranked

1305
citing authors

#	ARTICLE	IF	CITATIONS
1	Probing Fluorinated Motifs onto Dual AChE-MAO B Inhibitors: Rational Design, Synthesis, Biological Evaluation, and Early-ADME Studies. <i>Journal of Medicinal Chemistry</i> , 2022, 65, 3962-3977.	2.9	18
2	Lead exposure of rats during and after pregnancy induces anti-myelin proteolytic activity: a potential mechanism for lead-induced neurotoxicity. <i>Toxicology</i> , 2022, 472, 153179.	2.0	6
3	Neuroprotective potential of isothiocyanates in an in vitro model of neuroinflammation. <i>Inflammopharmacology</i> , 2021, 29, 561-571.	1.9	23
4	Increasing Oxygen Partial Pressures Induce a Distinct Transcriptional Response in Human PBMC: A Pilot Study on the "Normobaric Oxygen Paradox". <i>International Journal of Molecular Sciences</i> , 2021, 22, 458.	1.8	36
5	High Surface Area Mesoporous Silica Nanoparticles with Tunable Size in the Sub-Micrometer Regime: Insights on the Size and Porosity Control Mechanisms. <i>Molecules</i> , 2021, 26, 4247.	1.7	22
6	Luminescent PLGA Nanoparticles for Delivery of Darunavir to the Brain and Inhibition of Matrix Metalloproteinase-9, a Relevant Therapeutic Target of HIV-Associated Neurological Disorders. <i>ACS Chemical Neuroscience</i> , 2021, 12, 4286-4301.	1.7	9
7	Differential Modulation of NF- κ B in Neurons and Astrocytes Underlies Neuroprotection and Antigliosis Activity of Natural Antioxidant Molecules. <i>Oxidative Medicine and Cellular Longevity</i> , 2019, 2019, 1-16.	1.9	24
8	Molecular structure and function of myelin protein PO in membrane stacking. <i>Scientific Reports</i> , 2019, 9, 642.	1.6	41
9	Dynamic changes of MMP-9 plasma levels correlate with JCV reactivation and immune activation in natalizumab-treated multiple sclerosis patients. <i>Scientific Reports</i> , 2019, 9, 311.	1.6	12
10	In vitro effect of antiretroviral drugs on cultured primary astrocytes: analysis of neurotoxicity and matrix metalloproteinase inhibition. <i>Journal of Neurochemistry</i> , 2018, 144, 271-284.	2.1	24
11	Liver Fibrosis in HCV Monoinfected and HIV/HCV Coinfected Patients: Dysregulation of Matrix Metalloproteinases (MMPs) and Their Tissue Inhibitors TIMPs and Effect of HCV Protease Inhibitors. <i>International Journal of Molecular Sciences</i> , 2016, 17, 455.	1.8	30
12	Cytotoxicity Study on Luminescent Nanocrystals Containing Phospholipid Micelles in Primary Cultures of Rat Astrocytes. <i>PLoS ONE</i> , 2016, 11, e0153451.	1.1	18
13	Integrin-targeting with peptide-bioconjugated semiconductor-magnetic nanocrystalline heterostructures. <i>Nano Research</i> , 2016, 9, 644-662.	5.8	19
14	Inhibitory Effect of Aqueous Extracts from Marine Sponges on the Activity and Expression of Gelatinases A (MMP-2) and B (MMP-9) in Rat Astrocyte Cultures. <i>PLoS ONE</i> , 2015, 10, e0129322.	1.1	13
15	Comparative analysis of protein profiles of aqueous extracts from marine sponges and assessment of cytotoxicity on different mammalian cell types. <i>Environmental Toxicology and Pharmacology</i> , 2014, 38, 1007-1015.	2.0	8
16	Impact of Manganese Neurotoxicity on MMP-9 Production and Superoxide Dismutase Activity in Rat Primary Astrocytes. Effect of Resveratrol and Therapeutical Implications for the Treatment of CNS Diseases. <i>Toxicological Sciences</i> , 2013, 135, 218-228.	1.4	35
17	Inhibition of Myelin-Cleaving Poteolytic Activities by Interferon-Beta in Rat Astrocyte Cultures. Comparative Analysis between Gelatinases and Calpain-II. <i>PLoS ONE</i> , 2013, 8, e49656.	1.1	12
18	In Vitro Downregulation of Matrix Metalloproteinase-9 in Rat Glial Cells by CCR5 Antagonist Maraviroc: Therapeutic Implication for HIV Brain Infection. <i>PLoS ONE</i> , 2011, 6, e28499.	1.1	22

#	ARTICLE	IF	CITATIONS
19	Structure-Dependent Inhibition of Gelatinases by Dietary Antioxidants in Rat Astrocytes and Sera of Multiple Sclerosis Patients. <i>Neurochemical Research</i> , 2011, 36, 518-527.	1.6	35
20	Apolipoprotein(a) inhibits lipopolysaccharide-induced IL-6 secretion in human astrocytoma cell line by interfering with lipopolysaccharide signaling. <i>Inflammation Research</i> , 2011, 60, 329-335.	1.6	1
21	Developmental omega-3 supplementation improves motor skills in juvenile-adult rats. <i>International Journal of Developmental Neuroscience</i> , 2009, 27, 599-605.	0.7	34
22	Cationic Liposomes Target Sites of Acute Neuroinflammation in Experimental Autoimmune Encephalomyelitis. <i>Molecular Pharmaceutics</i> , 2009, 6, 1363-1370.	2.3	26
23	The different forms of PNS myelin P0 protein within and outside lipid rafts. <i>Journal of Neurochemistry</i> , 2008, 107, 291-301.	2.1	15
24	Antiretroviral therapy inhibits matrix metalloproteinase-9 from blood mononuclear cells of HIV-infected patients. <i>Aids</i> , 2007, 21, 677-684.	1.0	34
25	Inhibitory Effect of Polyunsaturated Fatty Acids on MMP-9 Release from Microglial Cells—Implications for Complementary Multiple Sclerosis Treatment. <i>Neurochemical Research</i> , 2007, 32, 2184-2193.	1.6	44
26	The pH-dependent unfolding mechanism of P2 myelin protein: An experimental and computational study. <i>Journal of Structural Biology</i> , 2006, 153, 253-263.	1.3	7
27	Interferon-beta inhibits the expression of metalloproteinases in rat glial cell cultures: implications for multiple sclerosis pathogenesis and treatment. <i>Multiple Sclerosis Journal</i> , 2004, 10, 290-297.	1.4	49
28	Interaction of Myelin Basic Protein with Phospholipid Monolayers: A Mechanism of Protein Penetration. <i>Langmuir</i> , 2003, 19, 872-877.	1.6	42
29	Crystals of P2 myelin protein in lipid-bound form. <i>Journal of Structural Biology</i> , 2003, 142, 292-300.	1.3	13
30	Conformation of bovine myelin basic protein purified with bound lipids. <i>European Biophysics Journal</i> , 1999, 28, 351-355.	1.2	68
31	Purification of bovine P2 myelin protein with bound lipids. <i>NeuroReport</i> , 1998, 9, 2769-2773.	0.6	16
32	Metalloproteinases and their inhibitors as therapeutic targets for multiple sclerosis: current evidence and future perspectives. <i>Metalloproteinases in Medicine</i> , 0, Volume 4, 1-13.	1.0	8